HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma.
Koskela H, Li Y, Joutsiniemi T, Muranen T, Isoviita VM, Huhtinen K, Micoli G, Lavikka K, Marchi G, Hietanen S, Virtanen A, Hautaniemi S, Oikkonen J, Hynninen J.
Koskela H, et al.
Gynecol Oncol. 2024 Jan;180:91-98. doi: 10.1016/j.ygyno.2023.11.027. Epub 2023 Dec 6.
Gynecol Oncol. 2024.
PMID: 38061276
Free article.
Clinical Trial.